Gabapentin / Neurontin — Dementia & Cognitive Decline

GABAPENTIN / NEURONTIN — DEMENTIA & COGNITIVE DECLINE INVESTIGATION

NEW AND EMERGING PHARMACEUTICAL LITIGATION OPPORTUNITY

PPC SQUARED is evaluating marketing and claimant intake opportunities involving long-term gabapentin use and subsequent diagnoses of dementia, Alzheimer's disease, or significant cognitive impairment.

Recent medical research has identified a possible association between repeated gabapentin prescriptions and increased rates of cognitive impairment, prompting law firms to investigate potential pharmaceutical product liability claims.

Priority claimants include individuals who received six or more gabapentin prescriptions and subsequently developed medically documented dementia or substantial cognitive impairment, particularly before age 65.

PPC SQUARED is seeking qualified law firm partners interested in evaluating this emerging litigation and developing targeted claimant acquisition campaigns.

This litigation remains investigational. Medical causation and legal liability have not been established, and compensation is not guaranteed.

Proposed acquisition price per qualified signed case

$500

Subject to a written campaign agreement and attorney acceptance

I’M INTERESTED IN PLACING AN ORDER →

About this mass tort

GABAPENTIN (NEURONTIN) — DEMENTIA AND COGNITIVE IMPAIRMENT

LITIGATION OVERVIEW

Gabapentin is a widely prescribed medication originally approved for seizure management and subsequently approved for postherpetic neuralgia. It is also frequently prescribed for conditions such as chronic back pain, neuropathy, anxiety, and other disorders.

Neurontin is the original brand-name product associated with Pfizer. Gabapentin is also distributed by numerous generic pharmaceutical manufacturers.

EMERGING COGNITIVE SAFETY CONCERNS

Research published in Regional Anesthesia & Pain Medicine identified an association between repeated gabapentin prescriptions and increased diagnoses of dementia and mild cognitive impairment among patients treated for chronic lower back pain.

Researchers analyzing 26,416 propensity-score-matched patients reported higher rates of dementia and mild cognitive impairment among those receiving six or more gabapentin prescriptions.

A 2026 systematic review and meta-analysis also identified an association between gabapentinoid exposure and Alzheimer's disease-related dementias, but emphasized that available observational evidence does not establish causation.

POTENTIAL LEGAL CLAIMS

Attorneys are investigating whether manufacturers provided adequate warnings about possible long-term cognitive risks and whether particular patients may possess viable pharmaceutical injury claims.

Potential claims depend on applicable state law, manufacturer identification, medical evidence, causation, federal preemption, and other legal considerations.

CURRENT LITIGATION STATUS

This is an emerging legal investigation. No dedicated federal multidistrict litigation, global settlement, or established compensation schedule has been verified for gabapentin-related dementia claims as of October 2026.

LAW FIRM OPPORTUNITIES

PPC SQUARED is evaluating targeted consumer outreach, structured intake screening, medical documentation workflows, and campaign opportunities for law firms investigating potential gabapentin-related cognitive injuries.

All claimant qualifications, case acceptance decisions, and legal determinations remain the responsibility of participating attorneys.

No settlement or recovery is guaranteed.

Preliminary case criteria

Dementia & Cognitive Decline

Exclusions / review flags

Preexisting dementia, unsupported memory complaints, and cases with major unresolved causation concerns

Medical records and evidence

PROPOSED CLAIMANT SCREENING CRITERIA
1. Documented prescription and use of gabapentin or Neurontin.
2. Prefer six or more prescriptions, with greater priority given to 12 or more documented prescriptions.
3. Diagnosis of dementia, Alzheimer's disease, or substantial cognitive impairment following gabapentin exposure.
4. Preference for diagnosis before age 65.
5. Diagnosis or assessment by a neurologist, geriatric specialist, or other qualified medical professional.
6. Supporting prescription, pharmacy, and medical records available or reasonably obtainable.
7. Individual assessment of alternative causes and applicable legal requirements.
EVIDENCE TO COLLECT
Complete pharmacy dispensing history
Gabapentin brand and manufacturer information
Dates of prescriptions and refills
Daily dosage and duration of treatment
Original prescribing condition
Date of first documented cognitive symptoms
Date and type of cognitive diagnosis
Neurologist and specialist records
Neuropsychological testing
MRI, CT, and other relevant diagnostic findings
Prior neurological and psychiatric history
Potential alternative medical causes
Relevant family medical history
State of prescription, use, and diagnosis
Previous attorney representation or claim resolution
Applicable authorization and engagement documents
PROPOSED INJURY TIERS
TIER 1 — PRIORITY:
Dementia or Alzheimer's disease diagnosed before age 65, sustained documented gabapentin exposure, significant cognitive impairment, and supporting specialist records.
TIER 2 — SECONDARY:
Medically diagnosed dementia or significant mild cognitive impairment, repeated documented exposure, measurable functional limitations, and available medical records.
TIER 3 — ATTORNEY REVIEW:
Documented cognitive decline with incomplete neurological evaluation, limited prescription evidence, or significant unresolved causation questions.
PRELIMINARY SCREENING EXCLUSIONS
Memory complaints without medical evaluation
No credible documentation of gabapentin use
Cognitive impairment clearly predating gabapentin exposure without a separately supportable worsening theory
Missing information preventing manufacturer identification
Prior settlements or releases covering the same alleged injury
Existing representation without an authorized transfer
Generic-only exposure, later-onset disease, or competing medical explanations require individualized attorney review rather than an automatic determination of legal ineligibility.

What happens next

Review the campaign and submit a no-login inquiry
Confirm jurisdictions, criteria, and case volume with PPC SQUARED
Review applicable marketing agreement and terms
Receive case delivery and reporting through the private portal

Interested in placing an order →Ask a question

Published opportunity listings are marketing information only. No attorney-client relationship is created by viewing this page. Screening and case acceptance remain subject to medical and legal review. Case prices are proposals, not guarantees of delivery or recovery.